Abstract:AIM:To investigate the efficacy and safety of combined de novo lamivudine (LAM) and adefovir dipivoxil (ADV) therapy in hepatitis B virus (HBV)-related decompensated liver cirrhosis patients.METHODS:One hundred and forty patients with HBV-related decompensated cirrhosis were recruited, 70 patients were treated with combined LAM and ADV de novo therapy, and the other 70 patients were treated with LAM alone as controls. The follow-up period was 144 wk. All patients with LAM resistance were shifted to ADV.RESULTS:The percentage of HBV-related decompensated cirrhosis patients with undetectable HBV DNA in de novo combination group was 51.6% (33/64), 84.2% (48/57), and 92.3% (49/53) by weeks 48, 96, and 144, respectively. In monotherapy group, HBV DNA negativity rate was 46.1% (30/65), 56.1% (32/57), and 39.2% (20/51) by weeks 48, 96 and 144, respectively. There was a significant difference between the two groups by weeks 96 and 144 (P = 0.012 and 0.001). The hepatitis B e antigen seroconversion rate was 28.1% (9/32), 40.0% (12/30), and 53.6% (15/28) in the combination group by weeks 48, 96 and 144, respectively, and 24.2% (8/33), 31.0% (9/29), and 37.0% (10/27) by weeks 48, 96 and 144, respectively, in monotherapy group. A total of 68.6% (44/64), 84.2% (48/57), and 92.5% (49/53) patients achieved alanine aminotransferase (ALT) normalization by weeks 48, 96 and 144, respectively in the combination group. In monotherpy group, the ALT normalization rate was 64.6% (42/65) by week 48, 73.7% (42/57) by week 96, and 80.4% (41/51) by week 144. No patients in the combination group exhibited detectable resistance for at least 144 wk. The cumulative resistance rate in monotherapy group at weeks 48, 96, and 144 was 20.0%, 36.8%, and 56.9%. Both combination group and monotherapy group demonstrated an improvement in Child-Turcotte Pugh and Model for End-Stage Liver Disease scores at weeks 48, 96, and 144. All patients tolerated both combination and monotherapy. The ceratinine levels and glomerular filtration rate remained normal in all patients during the follow-up period.CONCLUSION:In HBV-related decompensated liver cirrhosis patients, the combined de novo LAM and ADV therapy is more efficacious and safer compared to LAM alone.

Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis

Finite nucleos(t)ide-analogue therapy for functional cure in HBeAg-negative chronic hepatitis B: recent development in the paradigm shift

Hepatocellular carcinoma reduced, HBsAg loss increased and survival improved after finite therapy in hepatitis B patients with cirrhosis

Progress in the Antiviral Treatment of HBV-related Cirrhosis

Management of Antiviral Resistance in Chronic Hepatitis B

Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure

Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy

Advances in the Pharmacological Management of Chronic Hepatitis B

Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B

Effects of Antiviral Therapy on Preventing Liver Tumorigenesis and Hepatocellular Carcinoma Recurrence

Antiviral Therapy for Hepatitis B Virus‐related Decompensated Cirrhosis

Evidence-Based Management of Oral Nucleos(t)ide Analogue Withdrawal in Virally Suppressed Patients with Chronic HBV Infection

Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy

Chronic Hepatitis B Finite Treatment: similar and different concerns with new drug classes

Efficacy of Combined Therapy in Patients with Hepatitis B Virus-Related Decompensated Cirrhosis.

Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy

HBV life cycle and novel drug targets

Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B

New advances in drug therapy of chronic hepatitis B infection

Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy